-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $352

Benzinga·11/13/2026 14:51:03
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $341 to $352.